Testing effectiveness (Phase 2)Study completedNCT00235300
What this trial is testing
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
Who this might be right for
Cadaveric Donor Renal TransplantationAcute Renal Allograft RejectionInduction Therapy
Genzyme, a Sanofi Company 240